Ismail Housni

Ismail Housni is a research associate at BioNTech SE since August 2023, focusing on immunoreceptor therapy using CAR-T cells to treat solid cancers in vivo models. Prior experience includes serving as an immunology research assistant at Bavarian Nordic from November 2019 to February 2023, and as a research associate at Friedrich-Alexander-Universität Erlangen-Nürnberg from October 2015 to September 2019, where research involved clinical studies in immunology related to Systemic Fibrosis Diseases and ILCs. Educational qualifications consist of a Master of Science in Biotechnology from Sheffield Hallam University (2014-2015), a traineeship in Pharmaceutical Biotechnology at Martin-Luther-Universität Halle-Wittenberg (2012-2013), and a Bachelor of Science in Pharmacy from Arab International University (2006-2011).